Sugi Predict

Sugi Predict / Compounds / SCHEMBL983577

SCHEMBL983577

SCHEMBL983577

CC(=O)/C=C\C=C(C)\C=C\C=C(C)\C=C\C=C\C(C)=C\C=C\C(C)=C\C=C1/C(C)=CC(O)CC1(C)C

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 8/20 0.40
▸ HIF1A Q16665 3/20 0.38
▸ LMNA P02545 3/20 0.38
▸ GMNN O75496 2/20 0.38
▸ PMP22 Q01453 2/20 0.38
▸ TSHR P16473 2/20 0.38
▸ APEX1 P27695 1/20 0.38
▸ ALDH1A1 P00352 8/20 0.37
▸ SMN1; SMN2 Q16637 2/20 0.37
▸ ALOX15 P16050 4/20 0.35
▸ RXRA P19793 5/20 0.34
▸ RARA P10276 4/20 0.34
▸ RARB P10826 4/20 0.34
▸ RARG P13631 4/20 0.34
▸ PTGS1 P23219 4/20 0.34
▸ CYP3A4 P08684 4/20 0.34
▸ RXRB P28702 2/20 0.34
▸ RXRG P48443 2/20 0.34
▸ RORC P51449 2/20 0.34
▸ ADORA3 P0DMS8 2/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18582741 1.00 MAPT (0.40) MAPTHIF1ALMNAGMNNPMP22
SCHEMBL2841262 0.94 MAPT (0.41) MAPTHIF1ALMNAGMNNPMP22
SCHEMBL18582776 0.94 MAPT (0.41) MAPTHIF1ALMNAGMNNPMP22
SCHEMBL982343 0.94 MAPT (0.41) MAPTHIF1ALMNAGMNNPMP22
SCHEMBL1463072 0.94 MAPT (0.41) MAPTHIF1ALMNAGMNNPMP22
SCHEMBL15286195 0.90 MAPT (0.36) MAPTHIF1ALMNAGMNNPMP22
SCHEMBL2842094 0.89 MAPT (0.42) MAPTHIF1ALMNAGMNNPMP22
SCHEMBL983165 0.85 MAPT (0.39) MAPTHIF1ALMNAGMNNPMP22
SCHEMBL983166 0.85 MAPT (0.39) MAPTHIF1ALMNAGMNNPMP22
SCHEMBL18582730 0.85 MAPT (0.39) MAPTHIF1ALMNAGMNNPMP22

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 220 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2013144595-A1 PERIDININ-CHLOROPHYLL BINDING PROTEINS PROTEIN TECHNOLOGIES LIMITED (GB) 2013-10-03 — — WO claimed
US-20260144834-A1 ANTIMICROBIAL FEED ADDITIVE Axitan Ltd. (GB) 2026-05-28 — — US disclosed
US-20260123660-A1 Particles Containing a Lipid Matrix Core and Active Ingredient LONZA SALES AG (CH) 2026-05-07 — — US disclosed
EP-4054348-B1 PARTICLES CONTAINING A LIPID MATRIX CORE AND ACTIVE INGREDIENT LONZA SALES AG (CH) 2026-01-28 — — EP disclosed
US-12471609-B2 Reducing the risk of viral infection due to viral contaminated feed NOVUS INTERNATIONAL, INC. (US) 2025-11-18 — — US disclosed
US-12465075-B2 Particles containing a lipid matrix core and active ingredient LONZA SALES AG (CH) 2025-11-11 — — US disclosed
EP-4642253-A1 USE OF MICROALGAE AND MICROALGAE DERIVED COMPONENTS IN CULTIVATED FOOD PRODUCTION Weforesea Ltd. (IL) 2025-11-05 — — EP disclosed
US-20250281440-A1 METHOD TO IMPROVE GROWTH PERFORMANCE, LIVABILITY, CARCASS CHARACTERISTICS AND/OR MILK QUALITY IN SWINE NUTRIQUEST, LLC 2025-09-11 — — US disclosed
US-12349704-B2 High quality cultured meat, compositions and methods for producing same ALEPH FARMS LTD. (IL) 2025-07-08 — — US disclosed
US-12310386-B2 Reducing the risk of viral infection due to viral contaminated feed NOVUS INTERNATIONAL, INC. (US) 2025-05-27 — — US disclosed
US-20050065097-A1 Carotenoid ether analogs or derivatives for the inhibition and amelioration of ischemic reperfusion injury CARDAX PHARMACEUTICALS, INC. 2005-03-24 — — US disclosed
US-20050059635-A1 Carotenoid ester analogs or derivatives for controlling C-reactive protein levels CARDAX PHARMACEUTICALS, INC. 2005-03-17 — — US disclosed
US-20050059659-A1 Carotenoid analogs or derivatives for controlling C-reactive protein levels CARDAX PHARMACEUTICALS, INC. 2005-03-17 — — US disclosed
US-20050049248-A1 Carotenoid ether analogs or derivatives for controlling C-reactive protein levels CARDAX PHARMACEUTICALS, INC. 2005-03-03 — — US disclosed
US-20050037995-A1 Carotenoid ester analogs or derivatives for the inhibition and amelioration of ischemic reperfusion injury CARDAX PHARMA, INC. 2005-02-17 — — US disclosed
US-20050026874-A1 Carotenoid ether analogs or derivatives for the inhibition and amelioration of liver disease CARDAX PHARMACEUTICALS, INC. 2005-02-03 — — US disclosed
US-20050009930-A1 Carotenoid analogs or derivatives for controlling connexin 43 expression CARDAX PHARMA, INC. 2005-01-13 — — US disclosed
US-20050009788-A1 Carotenoid ester analogs or derivatives for controlling connexin 43 expression CARDAX PHARMACEUTICALS, INC. 2005-01-13 — — US disclosed
US-20050009758-A1 Carotenoid ether analogs or derivatives for the inhibition and amelioration of disease CARDAX PHARMA, INC. 2005-01-13 — — US disclosed
US-20050004235-A1 Carotenoid analogs or derivatives for the inhibition and amelioration of liver disease CARDAX PHARMACEUTICALS, INC. 2005-01-06 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050037995-A1 Carotenoid ester analogs or derivatives for the inhibition and amelioration of ischemic reperfusion injury CPT1A, TXNRD2, PC MAPT 4758/4885HIF1A 1596/4885LMNA 1111/4885
US-20260144834-A1 ANTIMICROBIAL FEED ADDITIVE ELOVL6, CROCC, ELOC MAPT 3063/4885HIF1A 2444/4885LMNA 2049/4885
US-20250281440-A1 METHOD TO IMPROVE GROWTH PERFORMANCE, LIVABILITY, CARCASS CHARACTERISTICS AND/OR MILK QUALITY IN SWINE PIGS, GLO1, IGFBP6 MAPT 3007/4885HIF1A 1654/4885LMNA 1769/4885
US-20050009788-A1 Carotenoid ester analogs or derivatives for controlling connexin 43 expression GJA1, GJB2, CRY1 MAPT 4813/4885HIF1A 2345/4885LMNA 29/4885
US-20050009930-A1 Carotenoid analogs or derivatives for controlling connexin 43 expression GJA1, GJB2, CRY1 MAPT 4766/4885HIF1A 2311/4885LMNA 34/4885
US-20050059635-A1 Carotenoid ester analogs or derivatives for controlling C-reactive protein levels TTPA, PROC, RBP4 MAPT 3857/4885HIF1A 4080/4885LMNA 3024/4885
US-20050059659-A1 Carotenoid analogs or derivatives for controlling C-reactive protein levels RBP1, PROC, RBP4 MAPT 3997/4885HIF1A 3872/4885LMNA 2708/4885
US-20050026874-A1 Carotenoid ether analogs or derivatives for the inhibition and amelioration of liver disease GYS2, HCCS, CPT1A MAPT 3961/4885HIF1A 4172/4885LMNA 716/4885
US-20260123660-A1 Particles Containing a Lipid Matrix Core and Active Ingredient AUP1, MGLL, MBOAT4 MAPT 440/4885HIF1A 3345/4885LMNA 1876/4885
US-20050049248-A1 Carotenoid ether analogs or derivatives for controlling C-reactive protein levels PROC, TTPA, CYC1 MAPT 4035/4885HIF1A 4422/4885LMNA 2351/4885
US-20050065097-A1 Carotenoid ether analogs or derivatives for the inhibition and amelioration of ischemic reperfusion injury TXNRD2, GPX4, PC MAPT 4751/4885HIF1A 1781/4885LMNA 868/4885
US-20050009758-A1 Carotenoid ether analogs or derivatives for the inhibition and amelioration of disease NFE2L2, GPX4, CYP11B2 MAPT 4360/4885HIF1A 2693/4885LMNA 685/4885
US-20050004235-A1 Carotenoid analogs or derivatives for the inhibition and amelioration of liver disease GYS2, HCCS, CPT1A MAPT 3908/4885HIF1A 4038/4885LMNA 870/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.